MapLight Therapeutics, Inc. (MPLT)
30.27
+2.47
(+8.88%)
USD |
NASDAQ |
Jun 11, 16:00
30.27
0.00 (0.00%)
After-Hours: 19:40
MapLight Therapeutics Debt to Equity Ratio : 0.014 for March 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.014 |
| December 31, 2025 | 0.0127 |
| September 30, 2025 | 0.0257 |
| June 30, 2025 | 0.0973 |
| Date | Value |
|---|---|
| March 31, 2025 | 0.0688 |
| June 30, 2024 | |
| March 31, 2024 | 0.0336 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Mineralys Therapeutics, Inc. | 0.00 |
| Evommune, Inc. | 0.0299 |
| Arrowhead Pharmaceuticals, Inc. | 2.237 |
| Oncolytics Biotech, Inc. | -0.099 |
| Sangamo Therapeutics, Inc. | -1.020 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 418.79M |
| Total Liabilities (Quarterly) | 18.95M |
| Shareholders Equity (Quarterly) | 399.83M |
| Current Ratio | 22.91 |
| Net Debt Paydown Yield | -0.12% |